Strong Earnings Lift Abbott Laboratories Shares

ABT is a global healthcare company with that offers cardiovascular and diabetes devices, nutritional products, diagnostic equipment, and branded generic drugs. Roughly 60% of its sales come from international markets. The company is seeking growth by looking to diversify its products, broaden research efforts, and invest strategically.

As for earnings, ABT’s fourth-quarter fiscal 2024 earnings report showed sales growth of 9.5% for the year (excluding COVID testing). The medical devices segment led the way, growing 14% on its own. ABT’s adjusted per-share earnings grew 13% in the fourth quarter over the prior year, and the company is guiding for more growth in 2025 – EPS of up to $5.25 and organic sales growth of up to 8.5%.

It’s no wonder ABT shares are up 22% this year – and they could rise more. MAPsignals data shows how Big Money investors are betting heavily on the forward picture of the stock.

Big Money Buys Abbott Laboratories

Institutional volumes reveal plenty. Recently, ABT has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in ABT shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Abbott Laboratories.

Abbott Laboratories Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, ABT has had strong profits and earnings growth:

• Profit margin (+31.8%)
• 3-year EPS growth rate (+38.9%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +10.8%.

Now it makes sense why the stock has been powering to new heights. ABT has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

Abbott Laboratories has been a top-rated stock at MAPsignals for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Top 20 report multiple times in the last decade. The blue bars below show when ABT was a top pick…climbing higher with time:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Abbott Laboratories Price Prediction

The ABT rally isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in ABT at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MAPsignals process here.